Remove Bacteria Remove DNA Remove Genomics Remove Protein
article thumbnail

Leading innovators in CRISPR nucleases for the pharmaceutical industry

Pharmaceutical Technology

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. CRISPR nucleases serve as an important genome editing tool.

In-Vivo 162
article thumbnail

How digital innovation is helping therapeutics to get to market faster

Drug Discovery World

Sanofi has stated that it intends to become the first pharma company “powered by AI at scale”, and as part of this ambition, agreed a collaboration with BioMap to co-develop advanced AI models and protein Large Language Models that that it hopes will enable biologics design and multiparametric optimisation 2. Obulytix is not alone.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The future of genomic medicine: can it fulfil its promises?

pharmaphorum

Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. I saw this, in particular, with the finishing of the human genome,” says Charlie. “At In reality, finishing the human genome was the first step of what is a long journey.”.

Genome 118
article thumbnail

Winship Cancer Institute of Emory University Joins Caris’ Precision Oncology Alliance

The Pharma Data

By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence® platform, physicians from Winship will be able to further prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients.

article thumbnail

Women in Science Who Have Paved the Way Forward in Genetics

XTalks

The Human Genome Project recently marked 20 years since the publication of the first full sets of human genomic sequences, an endeavor that spanned well over a decade. Today, new next-generation sequencing technologies allow for the sequencing of complex genomes within just a day or two.

Genetics 119
article thumbnail

The doors CRISPR libraries have and will open in phenotypic drug screening 

Drug Discovery World

Steve Wowk , VP, Business Unit and General Management of Integrated DNA Technologies, shared with DDW the value of CRISPR-Cas9 in drug discovery. In an effort to defend themselves against viral infection, bacterial cells capture and copy DNA fragments of bacteriophages into their genome.

Genome 52
article thumbnail

The future outlook for mRNA therapies

Drug Discovery World

Its job is to carry coding information that is essential to the translation and processing of functional proteins. This is essential to its use as a therapeutic agent and gives the technology a vast versatility making it suitable to treating a wide range of diseases – especially those that have high protein expression.

RNA 52